Academic Journal
Is bacterial lysate add-on therapy a cost-effective strategy for childhood asthma? Evidence from a Colombian economic model.
| Τίτλος: | Is bacterial lysate add-on therapy a cost-effective strategy for childhood asthma? Evidence from a Colombian economic model. |
|---|---|
| Συγγραφείς: | Buendía JA; Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Medellín, Colombia., Buendia Sánchez JA; Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Medellín, Colombia. |
| Πηγή: | Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2026 Jul; Vol. 27 (10), pp. 1029-1036. Date of Electronic Publication: 2026 May 04. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 100897346 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7666 (Electronic) Linking ISSN: 14656566 NLM ISO Abbreviation: Expert Opin Pharmacother Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare Original Publication: London : Ashley Publications, c1999- |
| Ιατρικοί όροι (MeSH): | Asthma*/economics , Asthma*/drug therapy , Asthma*/therapy , Cell Extracts*/economics , Cell Extracts*/therapeutic use , Cell Extracts*/administration & dosage , Anti-Asthmatic Agents*/economics , Anti-Asthmatic Agents*/therapeutic use , Anti-Asthmatic Agents*/administration & dosage, Humans ; Colombia ; Cost-Benefit Analysis ; Models, Economic ; Child ; Markov Chains ; Quality-Adjusted Life Years ; Cost-Effectiveness Analysis ; Bacterial Lysates |
| Περίληψη: | Introduction: Despite optimized standard therapy, many children with asthma continue to experience recurrent exacerbations. Bacterial lysates have demonstrated clinical benefits in reducing respiratory infections and asthma exacerbations, but their economic value in low- and middle-income countries remains uncertain. This study evaluated the cost-utility of bacterial lysate add-on therapy compared with standard care in children with mild-to-moderate asthma in Colombia. Methods: A probabilistic Markov decision-analytic model was developed to estimate costs and quality-adjusted life years (QALYs) from a third-payer perspective over a 1-year time horizon. Cost-effectiveness was assessed using a willingness-to-pay threshold of US$5,180 per QALY gained. Results: Bacterial lysate add-on therapy was undominated, with a total cost of US$1,369 and an incremental cost of US$72 compared with standard care. The net monetary benefit was US$3,444 for bacterial lysate add-on therapy versus US$3,361 for standard care. Conclusions: From a probabilistic economic perspective, bacterial lysate add-on therapy appears to be an economically efficient adjunct strategy, with modest individual-level benefits but a high probability of cost-effectiveness within resource-constrained healthcare settings. These findings should be interpreted in the context of model assumptions and the short-term time horizon. |
| Contributed Indexing: | Keywords: Bacterial lysate; Colombia; asthma; childhood; cost |
| Substance Nomenclature: | 0 (Bacterial Lysates) 0 (Cell Extracts) 0 (Anti-Asthmatic Agents) 0 (Broncho-Vaxom) |
| Entry Date(s): | Date Created: 20260428 Date Completed: 20260715 Latest Revision: 20260715 |
| Update Code: | 20260715 |
| DOI: | 10.1080/14656566.2026.2667331 |
| PMID: | 42047349 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1744-7666 |
|---|---|
| DOI: | 10.1080/14656566.2026.2667331 |